相关实验视频
Updated: Jun 9, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.9K
CBD对帕金森病的潜在影响:一个更新的概述
El Ghachi Hafida1, Soulimani Rachid2, Gamrani Halima1
1Neurosciences, Pharmacology, and Environment Unit (NPEU), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakesh, Morocco.
Open medicine (Warsaw, Poland)
|October 31, 2024
概括
在早期研究中,大麻素 (CBD) 对帕金森病 (PD) 症状显示出希望. 然而,需要更多的临床试验来证实CBD对PD的运动和非运动方面的有效性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 呈现出显著的运动和非运动症状,影响生活质量.
- 像l-DOPA这样的当前治疗方法有局限性和副作用,需要替代疗法.
- Cannabidiol (CBD) 是一种非精神活性大麻化合物,目前正在研究其治疗潜力.
研究的目的:
- 审查CBD在治疗帕金森病的运动和非运动症状方面的疗效.
- 巩固关于CBD治疗PD的临床前研究和临床试验的发现.
主要方法:
- 临床前动物研究的系统审查.
- 对帕金森病患者中CBD可用的临床试验数据的分析.
主要成果:
- 临床前研究表明,CBD对PD有潜在的益处.
- 现有的临床试验数量有限 (有七项),这阻碍了关于疗效的最终结论.
- 关于CBD对运动和非运动症状的影响的数据仍在出现.
结论:
- 根据临床前证据,CBD表明对帕金森病的治疗有希望.
- 进一步进行广泛的临床研究至关重要,以验证CBD在PD患者的疗效和安全性.
- 识别研究差距对于未来研究CBD在治疗PD症状中的作用至关重要.
相关概念视频
Parkinson's Disease: Overview
483
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
483
Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
163
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
163

